DocumentsDate added
Original article
Subrat Chandra1, Sushil Kumar Shukla2*,Dushyant Gaur3 Pooja Gupta4
1Associate Professor, Department of Pathology, Ram Manohar Lohia Institute of Medical Sciences, Vibhuti Khand, Gomti Nagar, Lucknow, India
2Associate Professor, Department of Community Medicine, UP RIMSR, Saifai, Etawah, UP, India
3 Professor & Head, Department of Pathology, HIMS, Dehradun, India
4 Associate Professor, Department of Obs. & Gyn., UP RIMSR, Saifai, Etawah, UP, India
Address reprint requests to
*Dr. Sushil Kumar Shukla,
Associate Professor, Department of Community Medicine, UP RIMSR, Saifai,Etawah, UP, India
Article citation: Chandra S, Shukla S, Gaur D, Gupta P. A cross-sectional study to identify the proportion of anaplastic carcinoma in thyroid cancer cases reporting to HIMS, Dehradun, India. J Pharm Biomed Sci 2015;05(10):817–821.Available at www.jpbms.info
Abstract
Background Anaplastic carcinoma of the thyroid (ATC) is the most aggressive thyroid gland malignancy. Although ATC accounts for less than 2% of all thyroid cancers, it causes up to 40% of deaths from thyroid cancer. Anaplastic carcinoma consists partly or entirely of undifferentiated cells. This represents 10% of all thyroid carcinomas and this is the most aggressive neoplasm of this gland.
Objective To estimate the proportion of anaplastic carcinoma and its subtypes. Methods and Results We studied 150 cases out of which 15 were reported as thyroid malignancy. Anaplastic carcinomas are reported here in four cases of middle age 5th and 6th decay of their life, two male and two female 1:1 with history suggestive of hyperthyroidism in three cases and euthyroid in one case. The tumours were of variable size and showed large pleomorphic cells in clusters as well as in an isolated form. The femaleto- male ratio was approximately 3:1. Peak incidence occurs during the third to fourth decades of life. The age range of affected patients reportedly is 15–70 years.
Conclusion ATC is a very uncommon malignancy but in our study we found four cases and we confirmed it by histopathological examination.
KEYWORDS anaplastic carcinoma, thyroid cancer, neoplastic lesions, hyperthyroidism, euthyroid
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research,patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Megha Pawar*, Rabindra N. Misra, Nageswari R. Gandham, Kalpana Angadi, Savita Jadhav,Chanda Vyawahare, Swarupa Hatolkar
Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune 411018, Maharashtra, India
Address reprint requests to
*Megha Pawar,
Research scholar,
Department of Microbiology
Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pune 411018,Maharashtra, India
Article citation: Pawar M, Misra RN,Gandham NR, Angadi K, Jadhav S,Vyawahare C, Hatolkar S. PREVALENCE AND ANTIFUNGAL SUSCEPTIBILITY PROFILE OF CANDIDA SPECIES ISOLATED FROM TERTIARY CARE HOSPITAL, INDIA. J Pharm Biomed Sci 2015;05(10):812–816.Available at www.jpbms.info
Abstract
Background The change in epidemiology and antifungal susceptibility has generated interest among clinical microbiologists in the identification of Candida up to species level along with antifungal susceptibility patterns. Objectives This study was undertaken to INVESTIGATE the PREVALANCE of Candida spp and its antifungal susceptibility from the various clinical samples.Materials and Methods Total of 317 clinical samples from various suspected fungal infections were received in the Department of Microbiology to investigate suspected Candidal infections. Isolation, identification and antifungal susceptibility were done by standard conventional methods.Results A total of 104 non-duplicate Candida species were isolated, out of which 37 (35.6%) were C. albicans and 67 (64.4) were non-C. albicans, and the remaining were C. tropicalis 35 (33.7%), C. glabrata 18 (17.3%) and C. parapsilosis 6 (5.8%). Maximum isolates were from sputum as well as body fluids followed by pus, tissue and urine. Antifungal susceptibility showed higher degree of resistance to Fluconazole (4%), followed by Clotrimazole (2%) and lower degree to Amphotericin B (1%). All isolates were susceptible to Ketoconazole, Voriconazole and Nystatin.
Conclusion An increase in the infections was caused by non-candida albicans species. Candida species identification and antifungal susceptibility are important for the treatment especially for those who hospitalise with serious underlying disease.
KEYWORDS antifungal susceptibility testing, Candida species, CHROM agar, Sabouraud’s dextrose agar (SDA)
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research,patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Moulshree Kohli1,Puneet Ahuja2, Amit Gupta3*
1 Post graduate student, Department of Oral and Maxillofacial Pathology and Microbiology, I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
2 Prof & Head, Department of Oral and Maxillofacial Pathology and Microbiology, I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
3Senior Lecturer, Department of Oral and Maxillofacial Pathology and Microbiology, I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
Address reprint requests to
*Dr. Amit Gupta,
Department of Oral and Maxillofacial Pathology and Microbiology, ITS Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
Article citation: Kohli M, Ahuja P, Gupta A. EVALUATION OF DIFFERENT DECALCIFYING AGENTS ON ORAL HARD TISSUES:A COMPARATIVE STUDY.J Pharm Biomed Sci 2015;05(10):804–806. Available at www.jpbms.info
Introduction Decalcification of bone and teeth is often an essential and important step during tissue processing. The rate of decalcification and the effect of various decalcifying agents on the tissue and their staining characteristics are two important parameters influencing the selection of decalcifying solutions. Some decalcifying agents, although they completely and rapidly remove the calcium ions also adversely affect the staining characteristics and may cause damage to the organic components. This study aimed to EVALUATE the efficacy of the commonly used demineralizing agents to identify the best decalcifying agent. Materials and Methods Three decalcifying agents namely, 10 percent nitric acid, 10 percent hydrochloric acid and 10 percent formic acid were used to decalcify 30 natural teeth.The endpoint of decalcification was EVALUATED by physical and chemical methods. The decalcified teeth were subjected to routine processing and staining with hematoxylin and eosin stains.
Result Formic acid of 10% was the most considerate to the hard tissues and 10% hydrochloric acid was the least considerate to the tooth structure.
Conclusion Formic acid of 10% though being the slowest decalcifying agent, gave excellent results for soft-tissue integrity and staining characteristics.
KEYWORDS 10% nitric acid, 10% hydrochloric acid, 10% formic acid, decalcifying agents
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Case Report
Amit Gupta1*, Puneet Ahuja2, Swyeta Jain Gupta3,Vivek Gautam4,Vivek Rai5
1Senior Lecturer, Department of Oral and Maxillofacial Pathology and Microbiology, I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
2 Prof & Head, Department of Oral and Maxillofacial Pathology and Microbiology, I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
3Senior Lecturer, Department of Periodontics and Implantology, I.T.S.Centre for Dental Studies and Research, Ghaziabad, Uttar Pradesh, India
4MDS,Prosthodontics (Private practitioner),Gautam Multispeciality Dental Clinic,P N Plaza Complex, Below Bank Of India,Sigra, Varanasi, Uttar Pradesh, India
5 MDS, Endodontics, Private Practitioner,Lucknow,Uttar Pradesh, India
Address reprint requests to
Dr. Amit Gupta,
Department of Oral and Maxillofacial Pathology and Microbiology,
I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
Article citation: Gupta A, Ahuja P,Gupta SJ, Gautam V, Rai V. Critical role of tumor marker biology in the assessment of radiotherapy as a therapeutic modality in oral squamous cell carcinoma. J Pharm Biomed Sci 2015;05(10):799–806. Available at www.jpbms.info
ABSTRACT Despite advances in oncology therapeutics and biomedical research that have transformed since the turn of this century and deepened our understanding of cancer hallmarks, resulting in the discovery and development of targeted therapies, the success rates of oncology drug development remain low. Opportunities have increased with the understanding of molecular basis of the cancer translating to the discovery, development and availability of targeted therapies that have brought meaningful benefit to patients with diverse malignancies. One of the most challenging aspects of head and neck oncology is the selection of the most appropriate treatment for an individual patient with squamous cell carcinoma. The encouraging results from neoadjuvant chemotherapy and radiotherapy for patients with larger tumours, call for the identification of new accurate predictors of response to radiotherapy so that the appropriate therapy can be tailored better for individual patients.
KEYWORDS radiotherapy, squamous cell carcinoma, tumour markers
REFERENCES
1.Bucci MK, Bevan A, Roach M 3rd. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin. 2005;55:117–34.
2.Chapman JD. Single-hit mechanism of tumour cell killing by radiation. Int J Radiat Biol. 2003;79(2):71–81.
3.Sinclair WK, Morton RA. Variations in X-ray response during the division cycle of partially synchronized Chinese hamster cells in culture. Nature. 1963;199:1158–60.
4.Vikram B, Strong EW, Shah JP, Spiro R. Failure in the neck following multimodality treatment for advanced head and neck cancer. Head Neck Surg. 1984;6(3):724–29.
5.Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol. 1996;40:197–223.
6.Littbrand B, Révész L. The effect of oxygen on cellular survival and recovery after radiation. Br J Radiol. 1969;42(504):914–24.
7.Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster SJ. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer. 1997;76(8):1046–54.
8.Brun E, Zätterström U, Kjellén E, Zatterstrom U, Kjellen E, Wahlberg P, et al. Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas. Acta Oncol. 2001;40:491–6.
9.Shintani S, Kiyota A, Mihara M, Nakahara Y, Terakado N, Ueyama Y, et al. Association of preoperative radiation effect with tumour angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn J Cancer Res. 2000;91(10):1051–7.
10.Aebersold DM, Beer KT, Laissue J, Hug S, Kollar A, Greiner RH, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Onocol Biol Phys. 2000;48:17–25.
11.Rosen EM, Fan S, Goldberg ID, Rockwell S. Biological basis of radiation sensitivity. Part 2: cellular and molecular determinants of radiosensitivity. Oncology (Williston Park). 2000;14(5):741–57; discussion 757–8.
12.Jayasurya R, Francis G, Kannan S, Lekshminarayanan K,Nalinakumari KR, Abraham T, et al. p53, p16 and cyclin D1: molecular determinants of response to radiotherapy treatment response in oral carcinoma. Int J Cancer. 2004;109(5):710–6.
13.Jeggo PA, Taccioli GE, Jackson SP. Menage à trios: double strand break repair, V(D)J recombination and DNA-PK. Bioassays.1995;17(11):949–57.
14.Gottlieb TM, Jackson S. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen.Cell. 1993;72(1):131–42.
15.Shintani S, Mihara M, Li C, Nakahara Y, Hino S, Nakashiro K, et al. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma.Cancer Sci. 2003;94(10):894–900.
16.Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.Lancet Oncol. 2001;2(11):667–73.
17.Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13(1):18–32.
18.Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9(Suppl 1):2–10.
19.Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Onocol Biol Phys. 2001;49(2):427–33.
20.Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000;18(10):2046–52.
21.Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002;24:792–9.
22.Terakado N, Shintani S, Yano J, Chunnan L, Mihara M, Nakashiro K,Hamakawa H. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol. 2004;40(4):383–9. Nikitakis NG, Sauk JJ, Papanicolaou SI. The role of apoptosis in oral diseases: mechanisms; aberrations in neoplastic,autoimmune; infectious; hematologic and developmental diseases; and therapeutic options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(4):476–90.
24.Loro LL, Vintermyr OK, Liavaag PG, Johannessen AC. Oral squamous cell carcinoma is associated with decreased bcl-2/bax expressed ratio and increased apoptosis. Hum Pathol. 1999;30(9):1097–105.
25.Xie X, Clausen OP, Boysen M. Prognostic value of Bak expression in oral tongue squamous cell carcinomas. Oncol Rep. 2003;10(2):369–74.
26.Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer. 1999;86(6):913–20.
27.Vora HH, Shah NG, Patel DD, Trivedi TI, Chikhlikar PR. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis. J Surg Oncol. 2003;82(1):34–50.
28.Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11(4):689–708.
29.Yarden Y. The EGFR family and its ligands in human cancer:signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–S8.
30.Song JI, Grandis JR. STAT signaling in head and neck cancer.Oncogene. 2000;19(21):2489–95.
31.Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(8):1935–40.
32.Gee JM, Nicholson RI. Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res. 2003;5(3):126–9.
33.Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, et al.Enhanced radiosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiationand 5-FU-induced production of IL-6 and IL-8. Int J Cancer.2004;108(6):912–21.
34.Baselga J. The EGFR as a target for anticancer therapy—focus on cetuximab. Eur J Cancer. 2001;37(Suppl 4):S16–S22.
Source of funding: None.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Case Report
Ambarisha Bhandiwad1, Surakshith L. Gowda2*
1Professor and Head, Department of OBG,JSS Medical College, JSS University,Mysore, Karnataka, India
2Junior Resident, Department of OBG, JSS Medical College, JSS University, Mysore,Karnataka, India
Address reprint requests to
*Dr. Surakshith L. Gowda,
No. 140/4, 2nd Cross, Shankarmutt road, Fort Mohalla,Mysore 570004, Karnataka, India
Article citation: Bhandiwad A, Gowda SL.Hepatitis E in pregnancy: a case report.J Pharm Biomed Sci 2015;05(10):797–798.Available at www.jpbms.info
ABSTRACT Viral hepatitis is one of the most common infectious diseases in developing countries. Hepatitis E in particular has a wide geographical variation and it either occur
as epidemics or seen as sporadic cases. Mainly when pregnant women are affected with Hepatitis E, the disease will be more severe if the women is in second or third trimester,
particularly in third trimester, where chances of fulminant hepatic failure is more with high mortality rates. Here we are presenting a case of acute viral hepatitis complicating pregnancy
where the women goes into spontaneous labour and almost ends in postpartum hemorrhage. Due to timely intervention by transfusing blood components the possible
harm was prevented. Each patient can behave in different way so the plan of management should be tailor made to each patient.
KEYWORDS Viral hepatitis, hepatitis E, pregnancy, fulminant hepatic failure, postpartum haemorrhage, component therapy
REFERENCES
1.Mall ML, Rai RR, Phillip M. Seroepidemiology of hepatitis A in India: changing pattern. Ind J Gastroenterol. 2001;20(4):130–2.
2.Aggarwall R, Jameel S. Hepatitis E. Hepatology. 2011;54(6):2218–26.
3.Taniguchi M, Kim SR, Mishiro S, Takahashi K, Shin MH, Yun H, et al. Epidemiology of hepatitis E in Northeastern China, South Korea and Japan. J Infect. 2009;58(3):232–7.
4.Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol. 2008;48(3):494–503.
5.Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med. 1981; 70(2):252–5.
6.Khuroo MS, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat. 2003;10:61–9.
7.Zhu G, Qu Y, Jin N, Sun Z, Liu T, Lee H, et al. Seroepidemiology and molecular characterization of hepatitis E virus in Jilin, China. Infection. 2008;36(2):140–6.
8.Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, et al. Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis. 2005;192(7):1166–72.
9.Ahmed A, Ali IA, Ghazal H, Fazili J, Nusrat S. Mystery of hepatitis E virus: recent advances in its diagnosis and management. Int J Hepatol. 2015;2015:872431.
Source of funding: None.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.